ClinicalTrials.gg
RecruitingNCT06200987Updated Mar 12, 2024

Penile Vibratory Stimulation in the Prevention of Sexual Dysfunction and Urinary Incontinence After Radical Prostatectomy

An interventional study of Penile vibrator in Erectile Dysfunction Following Radical Prostatectomy and Incontinence, sponsored by Herlev and Gentofte Hospital. Recruiting at 1 site in Denmark. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-03-12.

Sponsored by Herlev and Gentofte Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2024; still recruiting 2 years 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
100
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 18 studies in Erectile Dysfunction with a site in Denmark — 2 open to participants now, 3 under way, none of them phase 3. Erectile Dysfunction · Denmark.

Planned enrollment
4th of 14
100 · median 90
Started
2024
with 1 other
No phase
9 of 18
2 open now
Registered
16th of 18
by date
Lead sponsor
5 of 18
Herlev and Gentofte Hospital

Among the 18 studies in Erectile Dysfunction with a site in Denmark, this one is the 4th largest by planned enrollment of the 14 interventional ones that give a count, is one of 2 that started in 2024, is one of 9 with no phase, and was the 16th registered.

Erectile Dysfunction

702 studies on the registry are indexed under Erectile Dysfunction; 125 are open to participants now.

Browse Erectile Dysfunction studies →

Open to participants now

2 of the 18 studies in Erectile Dysfunction with a site in Denmark are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 78 Erectile Dysfunction studies recruiting now, 31 (40%) set no upper age limit and 34 (44%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 18 studies in Erectile Dysfunction with a site in Denmark, or all of them as a file.
02

Study summary

To investigate if post-operative penile vibration stimulation kan be used to reduce or prevent sexual dysfunction and urinary incontinence after radical prostatectomy. This will be done in a randomized, controlled, non-blinded study. Men that undergo nerve preserving surgery for prostate cancer is allocated into an intervention group and a control group. A total of 100 men will be included for a power of 80%. The intervention group will be instructed to use the "Ferticare 2.0" vibrator for at least five minutes a day with an amplitude of 1 mm and frequency of 90 Hz (these settings were found in a pilot study) for a total of 9 months.

Both groups will do the standard pelvic floor training program and both groups will be offered regular phosphodiesterase-5-inhibitor treatment. Before surgery, 3, 6 and 10 months after the patients will have to fill out four different questionnaires regarding sexual and urinary function, including IIEF-EF, EHS, "neglected side effects" and ICIQ-SF. (10 months is due to a wash-out period of 1 month after the intervention).

The collected data will be analysed and the primary goal is to see if there is a significant difference in average spontaneous IIEF-EF score in the two groups 10 months after the surgery.

Read the detailed description

Hypothesis The study's hypothesis is that vibration therapy, using the stimulation parameters found in the pilot study, will have a beneficial effect on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity.

Methods The study is conducted as a randomized, controlled non-blinded study. Men undergoing a nerve-sparing operation for prostate cancer are divided into two groups. A total of 100 men will be included in the study. In case a surgery cannot be performed with nerve preservation or if a participant experiences a recurrence of their prostate cancer requiring additional treatment, the participant will be withdrawn from the study.

Randomization and Treatment Overall, we will investigate the effect of vibration stimulation on erectile function, orgasm disturbances, penile shortening, and urinary incontinence, both generally and in connection with sexual activity. In accordance with the hypotheses, this study will offer vibration therapy for a longer duration than before. Both the vibration group and the control group will be offered fixed post-operative treatment with phosphodiesterase-5-inhibitors as per the standard protocol. Participants will be randomized into the two groups through drawing lots for either vibration or no vibration. Randomization will be done using block randomization via a computer-generated list. The "Ferticare 2.0" vibrator (produced by the company Reflexonic LLC, Leesburg VA, USA) will be used in the study, which is a modernized version of the previously used vibrator and is sold as a sexual aid in Denmark. It is safety-approved with European CE marking as a "household appliance" and is sold as a sexual aid in Denmark. Men in the vibration group will be instructed on the stimulation before their prostate surgery. Subsequently, participants will be able to perform the vibration therapy themselves at home. In both groups, participants must undergo a standard pelvic floor training program, and both groups will be offered fixed PDE-5 inhibitor treatment in the form of daily tadalafil, 5 mg, as the standard treatment for erectile difficulties after the operation. In the vibration group, daily stimulation will be directed towards the frenulum for a minimum of 5 minutes, with an amplitude of 1 mm and a frequency of 90 Hz, as found in the pilot study. Participants will start getting used to the vibration 1-4 weeks before the surgery and resume it within 14 days after the operation. The daily stimulation will continue for a period of 9 months, along with the standard treatment. After these 9 months, men in both groups will stop taking tadalafil during a 4-week wash-out period, after which their spontaneous sexual function will be evaluated. This is necessary due to the well-known positive effect of the medication. In comparison to the standard treatment in the department, offering vibration to half of the participants is an addition. Regarding pelvic floor training and medication for erectile difficulties for all study participants, the current standard is to offer these to all men who have undergone nerve-sparing radical prostatectomy. This will proceed as usual, and the only deviation from usual practice is ensuring that the medication offer is consistent for all participants. The mentioned 4-week period without tablet treatment (wash-out) is necessary to assess spontaneous erections. This is a deviation from the normal standard, as such a wash-out is not conducted for patients who do not participate in research, but it will not affect the actual erectile function of the participants in either group.

Data Collection

Standard investigations related to prostate cancer will be conducted according to normal guidelines, with the registration of:

  • Pre-operative PSA
  • Clinical and pathological tumor stage
  • Gleason score
  • Prostate size
  • Degree of nerve preservation during the surgery
  • Any complications during the surgery
  • Resection margin status (positive or negative)
  • PSA measurements at 3, 6, and 12 months after the operation. This information will be obtained from the patient's medical records by the scientific staff after the study participants have given their consent to participate. After providing consent, the study organizers, sponsor, sponsor's representatives, and any regulatory authorities will have direct access to obtain information from the patient's medical records, including electronic records, for the purpose of reviewing information about the research participant's health, as necessary for conducting the research project and for monitoring, including self-monitoring, quality control, and oversight, as they are obligated to perform.

Since potential participants are screened and informed about the project during their visits to the outpatient clinic (see the section on Recruitment of Study Participants and Informed Consent), there is no need to obtain information from the patient's medical records before consent is given. At this stage, the research team only receives the name, social security number, and contact information for patients who have expressed interest in the project.

Additional examinations are carried out before the surgery and at follow-ups at 3 months, 6 months, and 10 months (equivalent to the end of the wash-out period) after the surgery, with the registration of the following for all participants in both the vibration group and the control group:

Before the surgery and at follow-ups:

  • Validated symptom questionnaires for erectile function (IIEF-EF and EHS)
  • Specific questionnaire about orgasm disturbances, penile shortening, and urinary incontinence during sexual activity.
  • Validated symptom questionnaire for incontinence symptoms (ICIQ-SF)
  • 24-hour pad weighing test (only at follow-ups for men who are not fully continent)

Additional registrations at follow-ups:

  • Registration of PSA recurrence after the surgery and noting any additional treatment
  • Any side effects of vibration and standard treatment
03

Conditions studied

  • Erectile Dysfunction Following Radical Prostatectomy
  • Incontinence

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men who are undergoing nerve-sparing radical prostatectomy
  • Pre operative erectile function of IIEF-EF > 25
  • Sexually active . Continent before surgery defined as a score of 0 on the ICIQ-SF questionnaire

Exclusion criteria

Exclusion Criteria:

  • Urinary incontinent before surgery
  • Comorbidity that prevents the patient from taking PDE5-inhibitors
  • Disease in the penis or in the penile skin (Peyronies, phimosis)
  • Problems using the vibrator ie impaired function of the hands
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
100 participants (estimated)

Study arms

  • Experimental
    Intervention

    The group randomized to use the vibrator for 9 months

    Device: Penile vibrator

  • No intervention
    Controls

    Usual standard treatment

Interventions

  • DevicePenile vibrator

    In addition to standard treatment with PDE5-inhibitors the intervention is daily stimulation for five minutes with the vibrator for 9 months

06

What researchers measure

Primary outcomes

  1. Erectile function

    The erectile function compared to controls measured by IIEF-EF

    Time frame: 10 months

Secondary outcomes

  1. ICIQ-UI-SF: The International Consultation on Incontinence Questionnaire - Urinary Incontinence - short form

    Difference in ICIQ-SF score between the two groups after 3, 6 and 10 months. The score is from 0-21. The higher the score the more incontinent. A score of 0 is no urinary incontinence.

    Time frame: 10 months

  2. IIEF-EF score (The International Index of Erectile Function - Erectile Function)

    Difference in IIEF-EF score between the two groups after 3, 6 and 10 months. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.

    Time frame: 10 months

  3. Diaper weighing test

    Difference in 24 hour diaper weighing test between the two groups after 3, 6 and 10 months

    Time frame: 10 months

  4. IIEF-EF (The International Index of Erectile Function - Erectile Function) over 25

    The percentage of patients who gain a post-operative spontaneous IIEF-EF score of at least 25. The minimum score is 0 and the maximum score is 30. The higher the score the better erectile function.

    Time frame: 10 months

  5. EHS (Erection Hardness Scale)

    The percentage of patients who gain a post-operative spontaneous EHS of at least 3. The scale is from 0-4. 0 is no erection, the higher the score the better erection.

    Time frame: 10 months

  6. Neglected sexual side effects

    The presence of orgasm disturbances, penile shortening and urinary incontinence in relation to sexual activity.

    Time frame: 10 months

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Available upon request. Subject to approval from the Danish Data Protection Agency.

Supporting information: Study protocol, Statistical analysis plan

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2024 (actual). Primary completion is estimated for Mar 2026, 25 months after the start.

Of 115 non-industry interventional studies with no phase under Erectile Dysfunction, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 52. This study's planned 25 months is below that.

Counting every sponsor, half of 137 studies reached it within 32 months; a quarter within 14 and three quarters within 52.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 29, 2023
First posted
Jan 11, 2024
StartActual
Feb 1, 2024
Primary completionEst.
Mar 2026
CompletionEst.
Oct 2026
Last update
Mar 12, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 12, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06200987
Lead sponsor
Herlev and Gentofte Hospital
Responsible party
Helene Reif Andersen (PhD fellow, Herlev and Gentofte Hospital) — Principal investigator
First posted
Jan 11, 2024
Start date
Feb 1, 2024
Primary completion
Mar 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Mar 12, 2024

Study contacts

Helene R Andersen, MD
Contact
helene.reif.andersen@regionh.dk
+4538681507
Mikkel Fode, MD, PhD
principal investigator · Department of Urology, Herlev and Gentofte University Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion